weight loss drug prescriptions semaglutide tirzepatide q3 2024 data vs Tirzepatide: Which GLP-1 Wins for Loss? GLP-1 Antagonists Increase Plan Drug

You should not use the information on this website for diagnosing or treating a health problem or disease, or prescribing any medication or other treatment

It may be small differences such as this that result in improvement when switching from one medication to the other, even though technically they are the same thing

Notably, the cardiovascular outcomes study conducted on adults (SELECT study) revealed a higher incidence of hip and pelvic fractures among female patients receiving semaglutide compared to those on placebo: 1.0% (24/2448) versus 0.2% (5/2424) [80]

DeFoor and Dekker ( Arthroscopy , 2024) noted the scarce orthopaedic literature investigating the clinical use and outcomes of such therapeutic peptides while acknowledging that the market continues to expand rapidly

But sometimes the confusion sets in because some people dont really get the results